Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Items 901–1,000 of 1,010
Halder, D., Das, S., Jeyaprakash, R. S., & Joseph, A. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2158136 · Cited by 15
“The other factors, except age, are genetics, mild cognitive impairment, pollution, poor sleep cycle, and excessive alcohol and drug consumption (Bondi et al., 2017; Breijyeh & Karaman, 2020).”
BackgroundUnravelling Novel Phytochemicals and Anticholinesterase Activity in Irish Cladonia portentosa
Nagar, S., Pigott, M., Kukuła‐Koch, W., & Sheridan, H. (2023) · Molecules · doi:10.3390/molecules28104145 · Cited by 11
“Its pathogenesis is not fully understood, and there is no cure [26].”
BackgroundAnti-Alzheimer Drug Delivery via Pickering Emulsions Stabilized by Plate-like Cellulose Nanocrystals
Mikhaylov, V. I., Торлопов, М. А., Vaseneva, I. N., Legki, P. V., Михайлович, П. Н., Martakov, I. S., & Sitnikov, P. А. (2023) · Langmuir · doi:10.1021/acs.langmuir.3c01420 · Cited by 11
miR ‐6076 targets BCL6 in SH‐SY5Y cells to regulate amyloid‐β‐induced neuronal damage
Lin, Y., Zhang, L., Gao, M., Tang, Z., Cheng, X., Li, H., Qin, J., Tian, M., Jin, G., Zhang, X., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17999 · Cited by 11
Understanding Alzheimer’s Disease and its Metal Chelation Therapeutics: A Narrative Review
Thakur, R., Karwasra, R., & Umar, T. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128263992231012113847 · Cited by 11
Blood–brain barrier disruption in dementia: Nano‐solutions as new treatment options
Cooper, C. G., Kafetzis, K. N., Patabendige, A., & Tagalakis, A. D. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.16229 · Cited by 11
Cao, W., Ji, Z., Zhu, S., Wang, M., & Runming, S. (2024) · BMC Medical Genomics · doi:10.1186/s12920-023-01775-6 · Cited by 12
“Only two medication classes—cholinesterase inhibitors and N-methylD-aspar-tate antagonists—are currently licensed for the treatment of AD [10].”
BackgroundAdvancements in the study of synaptic plasticity and mitochondrial autophagy relationship
Zhu, Y., Hui, Q., Zhang, Z., Fu, H., Qin, Y., Zhao, Q., Li, Q., Zhang, J., Guo, L., He, W., et al. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25309 · Cited by 13
Alharbi, K. M., Alshehri, S. A., Almarwani, W. A., Aljohani, K., Albalawi, A. Z., Alatawi, A. S., Al-Atwi, S. M., Alhwyty, L. S., Hassan, H. M., & Al-Gayyar, M. M. H. (2024) · Current Alzheimer Research · doi:10.2174/0115672050315334240508162754 · Cited by 13
Mosalam, E. M., Elberri, A. I., Abdallah, M. S., Abdel‐Bar, H. M., Zidan, A. A., Batakoushy, H. A., & Mansour, H. E. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147790 · Cited by 11
“AD and dementia-related illnesses are the seventh most common causes of mortality and some of the main reasons why older people have disabilities [5].”
BackgroundMu, B., Jing, J., Li, R., & Li, C. (2024) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-024-10036-9 · Cited by 11
“Pathologically, the accumulation of neuritic plaques composed of β-amyloid (Aβ) could trigger neuronal dysfunction and apoptosis by interfering with neuron-to-neuron communication at synapses (Breijyeh 2020; , Sehar 2022).”
Dhurandhar, Y., Tomar, S., Das, A., Singh, A. K., Prajapati, J. L., Bodakhe, S. H., & Namdeo, K. P. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00338 · Cited by 11
Space exploration and risk of Parkinson’s disease: a perspective review
Ali, N., Beheshti, A., & Hampikian, G. (2025) · npj Microgravity · doi:10.1038/s41526-024-00457-6 · Cited by 14
Simultaneous binding of heme and Cu with amyloid β peptides: active site and reactivities
Nath, A. K., & Dey, S. G. (2022) · Dalton Transactions · doi:10.1039/d2dt00162d · Cited by 11
Changes in personality traits in patients with Alzheimer's Disease
Lopes, K. F., Bahia, V. S., Natividade, J. C., Bastos, R. V. S., Shiguti, W. A., da Silva, K. E. R., & de Souza, W. C. (2022) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2021-0029 · Cited by 11
Wang, Q. (2022) · Wireless Communications and Mobile Computing · doi:10.1155/2022/1374835 · Cited by 11
“More than 750,000 people in Britain suffer from senile dementia [3], and the number of dementia patients in China is about 7 million, which is estimated to exceed 22 million by 2040 [4].”
BackgroundProtective effects of phosphodiesterase 2 inhibitor against Aβ1-42 induced neuronal toxicity
Yan, Y., Gao, S., Avasthi, S., Zhao, Y., Ye, J., Tao, Y., Wang, W., Zhu, X., Du, F., O’Donnell, J. M., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109128 · Cited by 11
Courtier, A., Potheret, D., & Giannoni, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120689 · Cited by 11
You, M., Yuan, P., Li, L., & Xu, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066819 · Cited by 13
“Employing agents that target the pathological mechanisms underlying this disease in order to delay its development is of great importance (Cummings et al., 2019; Breijyeh and Karaman, 2020).”
BackgroundNath, A. K., Roy, M., Dey, C., Dey, A., & Dey, S. G. (2022) · Chemical Science · doi:10.1039/d2sc05008k · Cited by 11
Accuracy of Raman spectroscopy in the diagnosis of Alzheimer's disease
Xu, Y., Pan, X., Li, H., Cao, Q., Xu, F., & Zhang, J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1112615 · Cited by 14
Nguyen, V. B., Wang, S., Phan, T. Q., Đoàn, M. D., Phan, T. K. P., Phan, T. K. T., Pham, T. H. T., & Nguyen, A. D. (2023) · Life · doi:10.3390/life13061281 · Cited by 11
“This disease has been recorded as a global health issue, with the number of patients worldwide reaching approximately 50 million; the number of cases of AD may double every 5 years, and it is estimated to reach 152 million by 2050 [1,2].”
BackgroundYan, X., Zhang, J., Li, J., Zhang, X., Wang, Y., Chen, X.-L., Luo, P., Hu, T., Cao, X., Zhuang, H., et al. (2023) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2023.127289 · Cited by 12
Wahid, F., Jan, T., Al-Joufi, F. A., Ali Shah, S. W., Nisar, M., & Zahoor, M. (2022) · Brain Sciences · doi:10.3390/brainsci12070894 · Cited by 10
“The most effective strategy to treat AD is the use of inhibitors of acetylcholinesterases [9] as these enzymes hydrolyze acetylcholine (ACh), which is needed for nerve transmission, however, a normal phenomenon in certain pathological conditions is that its excessive activities lead to cholinergic deficit on one hand…”
BackgroundDiscovery of carbamate-based salicylic acid derivatives as novel cholinesterase inhibitor
Wang, Y., Long, L., Yu, Q., Zhang, H., Li, X., Zhuo, L., Wang, S., & Wang, Z. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.134804 · Cited by 10
Recent progress in biological activities of dihydropyrimidine derivatives: An updated mini-review
Elshamsy, A. M., Ali, T. F. S., Osman, M., & El‐Koussi, N. A. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.198467.1183 · Cited by 13
Optical Imaging Reveals Liver Metabolic Perturbations in Mblac1 Knockout Mice
Ceyhan, B., LaMar, J., Nategh, P., Neghabi, M., Konjalwar, S., Rodriguez, P., Hahn, M. K., Blakely, R., & Ranji, M. (2023) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc40787.2023.10341032 · Cited by 10
“In contrast, there are negative lesions, which refer to neural, neuropil and synaptic loss [4].”
BackgroundHe, J., Wang, P., He, J., Sun, C., Xu, X., Zhang, L., Wang, X., & Gao, X. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhae065 · Cited by 10
“Alzheimer’s disease (AD) is a neurodegenerative disorder and it is the predominant cause of dementia worldwide (Breijyeh and Karaman 2020).”
Abdullah, S. A., Cocklereece, I., & Dellinger, K. (2024) · Exploration of BioMat-X · doi:10.37349/ebmx.2024.00008 · Cited by 10
“Although isolation techniques that rely on sEVs protein markers antibody affinity binding are highly specific and increase purity, these techniques have several drawbacks, which include low sEVs yields and the high cost of antibodies.”
Li, X., Han, Z., & Li, H. (2024) · Biology · doi:10.3390/biology13060412 · Cited by 11
“Unfortunately, while effective in symptom management, these drugs are unable to halt disease progression or provide a curative solution [7].”
BackgroundGarcía-Zamora, M., García‐Lluch, G., Moreno, L., Pardo, J., & Cháfer‐Pericás, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107446 · Cited by 11
Isatin derived morpholine and piperazine derivatives as acetylcholinesterase inhibitors
Thomas, R. R., Trisciuzzi, D., Sudevan, S. T., Gambacorta, N., Catto, M., Kumar, S., Abdelgawad, M. A., El-Ghorab, A. H., Selim, S., Ghoneim, M. M., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140503 · Cited by 10
Revolutionizing Healthcare with Federated Learning: A Comprehensive Review
Mishra, S., Tandon, R., & Rathore, N. P. S. (2024) · IEEE International Conference on Advances in Computing Research on Science Engineering and Technology (ACROSET) · doi:10.1109/acroset62108.2024.10743932 · Cited by 11
Lin, L., Li, J., Yu, Z., He, J., Li, Y., Jiang, J., & Xia, Y. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149341 · Cited by 12
Retinal Microstructural and Microvascular Changes in Alzheimer Disease: A Review
Ordoñez, M. A. O., Smith, R. C., Yiu, G. C., & Liu, Y. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000549 · Cited by 12
Senescent microglia: The hidden culprits accelerating Alzheimer’s disease
Li, W., Xie, Y., Jia-Xin, M., Shu-Chao, G., & Li-Ping, H. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149480 · Cited by 11
Rahmatkar, S. N., & Singh, D. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04776-x · Cited by 11
“Anticholinergics induce cognitive abnormalities probably due to the presence of Aβ plaques, which lead to diminished ACh generation , release, neurotransmission, and degradation [108].”
A criterion characterizing accumulated neurotoxicity of Aβ oligomers in Alzheimer's disease
Kuznetsov, A. V. (2025) · Proceedings of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rspa.2024.0652 · Cited by 11
Insights From TgF344-AD, a Double Transgenic Rat Model in Alzheimer’s Disease Research
Nataraj, A., Blahna, K., & Ježek, K. (2025) · Physiological Research · doi:10.33549/physiolres.935464 · Cited by 10
“Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder and is the leading cause of dementia [1-3].”
PCSK9 in Vascular Aging and Age-Related Diseases
Tan, D., Yang, X., Yang, J., Fan, G., & Xiong, G. (2025) · Aging and Disease · doi:10.14336/ad.2024.1713 · Cited by 15
“Alzheimer’s disease (AD) is the most common form of dementia and can be defined as a gradually progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta peptide Aβ [155].”
Applications of event-related potentials in Alzheimer’s disease: a systematic review and analysis
Liang, Q., Chen, Z., Tang, X., & Wang, X. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1513049 · Cited by 12
Brain State Transition Disruptions in Alzheimer's Disease: Insights from EEG State Dynamics
Razavi, S. M., Tran, T. M., Wilson, S. E., & Khanmohammadi, S. (2025) · IEEE International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi60581.2025.10981035 · Cited by 10
“Around 57.4 million people were suffering from dementia in 2019 and these numbers are considered to increase to 152.8 million by 2050 [2, 3].”
InfluentialRecent Advances in Visual Dysfunction and Ocular Biomarkers in Neurological Disorders
Cheng, J., Paracha, S. S., Agrawal, S., Wu, Z., & Sung, C.-H. (2025) · Eye and Brain · doi:10.2147/eb.s516393 · Cited by 11
“74 However, these tests are invasive and costly.”
Updates on Tau-Related Drug Targets and Potential Disease-Modifying Therapies for Alzheimer Disease
Djurovic-Topalovic, A., Horgan, N. G., & Fortin, J. S. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.05.020 · Cited by 12
Computer-aided discovery of dual-target compounds for Alzheimer’s from ayurvedic medicinal plants
Shah, M., Pervaiz, S., Ahmad, I., Ansari, S. H., de Paula, V. F., Ahmed, S., Khan, M. U., Fawy, K. F., Nishan, U., Dib, H., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325441 · Cited by 11
“It also acts as a potent anti-oxidant, having a ki value of 50.96 ± 2.18µM for AChE [73].”
InfluentialDirir, A. M., Ali, A. H., & Hachem, M. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s537566 · Cited by 10
The Anti-Inflammatory Actions of Soluble Klotho in Brain Aging and Its Main Associated Diseases
López-Valdés, H. E., Hernández-Lucas, M., Rodríguez-Fabián, G. D. J., Esteban-Román, N. F., Gutiérrez-Juárez, R., Arrieta‐Cruz, I., & Martínez‐Coria, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178551 · Cited by 10
“…(A β ) protein that form extracellular plaques, and also intracellular accumulation of neurofibrillary tangles (NTF), which are the abnormal accumulation of hyperphosphorylated tau protein filaments, resulting in a loss of cytoskeletal microtubules and tubulin-associated proteins [120].”
Harun, Z. Z., Azhar, A. A., Kim, Y. J., Ibrahim, F. W., Ng, M. H., Tan, J. K., & Lokanathan, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13122931 · Cited by 11
“In AD, aggregation of amyloid beta (a β ) protein, which is caused by abnormal cleavage of amyloid precursor protein (APP), and deposition of neurofibrillary tangles (NFT), which is caused by hyperphosphorylation of tau protein, can be observed [6].”
Hydrophobic tagging: A promising paradigm for targeted protein degradation
Xin, L., Wang, H., Yang, M., Guo, Z., Zhu, M., Moore, T. W., Dong, C., & Zhou, H. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100295 · Cited by 14
“…of a definitive cure for NDs, researchers are vigorously investigating various therapeutic strategies to alleviate symptoms, with strategies including autophagy modulation, miRNA-based therapy, and stem cell therapy (Balestrino & Schapira, 2020; Breijyeh & Karaman, 2020; Van Bulck et al., 2019).”
Yuvika, Sharma, D., & Sharma, A. (2026) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2026.110473 · Cited by 13
A Network Pharmacology Based Research on the Mechanism of Donepezil in Treating Alzheimer's Disease
Liu, L., Zhu, Y., Fu, P., & Yang, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.822480 · Cited by 11
Xue, L., Huangfu, L., Du, R., Chen, L., Yu, C., Xiong, L., & Wang, T. (2022) · Neurological Research · doi:10.1080/01616412.2022.2112368 · Cited by 10
“Some studies have shown that lifestyle changes, such as diet and exercise, can improve brain health and reduce AD without the need for medical intervention, and are considered a first-line intervention for all AD patients [45,46].”
BackgroundJadoon, R., Javed, M. A., Jan, M. S., Ikram, M., Mahnashi, M. H., Sadiq, A., Shahid, M. A. R., & Rashid, U. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128994 · Cited by 15
Perus, L., Busto, G. U., Mangin, J., Bars, E. L., & Gabelle, A. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1014559 · Cited by 13
“Clinically, the typical form induces episodic memory deficit, progressively associated with language and behavioral troubles and leading to a loss of autonomy (DeTure and Dickson, 2019; Breijyeh and Karaman, 2020; Scheltens et al., 2021).”
BackgroundRoldán-Martín, L., Sodupe, M., & Maréchal, J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1110311 · Cited by 10
“Many efforts have been placed into discovering the onset of the disease and how to reverse it, but no effective treatments have been proposed so far (Breijyeh et al., 2020).”
BackgroundDuan, R., Hong, C., Chen, M., Wang, X., Pang, Z., Xie, H. W., & Liu, Z. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110462 · Cited by 11
Origins of nervous tissue susceptibility to ferroptosis
Snyder, J., & Wu, Z. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100091 · Cited by 10
Gräfe, E. L., Reid, H. M. O., Shkolnikov, I., Conway, K., Kit, A., Acosta, C., & Christie, B. R. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101076 · Cited by 10
Rastogi, V., Jain, A., Kumar, P., Yadav, P., Porwal, M., Chaturvedi, S., Chandra, P., & Verma, A. K. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2238250 · Cited by 10
“the origin of this disease involves vitamin B12 deficiency, tumour in the brain, and depleted oxygen supply to the brain due to the malfunctioning of the pulmonary and circulatory systems [1].”
BackgroundDEMENCIA POR CORPOS DE LEWY E ALZHEIMER: DIFERENÇA NO DIAGNÓSTICO
Nunes, V. E. S., Saraiva, M. G., Camelo, K. L. C., Nunes, C. E. B., Ribeiro, R. A. A., & Sobrinho, O. F. D. O. (2023) · Saúde Coletiva (Barueri) · doi:10.36489/saudecoletiva.2023v13i87p13001-13012 · Cited by 10
Huang, P., Lin, L., Zhang, J., Cheng, Y., & Pan, X. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2293225 · Cited by 10
de Oliveira, A. P., Chase, W., Confer, M. P., Walker, S., Baghel, D., & Ghosh, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04782 · Cited by 10
Borikar, S. P., Sonawane, D. S., Tapre, D. N., & Jain, S. P. (2024) · International Journal of Neuroscience · doi:10.1080/00207454.2024.2342973 · Cited by 12
“…psychiatrist, identified Alzheimer’s disease (AD) as the most prevalent form of dementia, is characterized by neuritic plaques and neurofibrillary tangles that form in the medial temporal lobe and other neocortical structures of the brain as a result of amyloid-beta (Aβ) peptide buildup [1,2].”
Kharat, S., Mali, S., Korade, G. S., & Rakhi, G. (2024) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001095 · Cited by 10
“The medial temporal lobe and neocortical regions of the brain, which are the most damaged parts of AD, have amyloid-beta peptide (A beta) buildup that causes neuritis plaques and neuro(cid:976)ibrillary tangles [18].”
Guo, J., Mo, H., Zuo, L., Liang, R., & Lyu, Q. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1390903 · Cited by 10
González‐Manzano, S., Ayuda‐Durán, B., Martín-Sanz, R., Garzón‐García, L., Santos‐Buelga, C., & Gonzaléz‐Paramás, A. M. (2024) · Foods · doi:10.3390/foods13233865 · Cited by 12
Abdalla, M., Khalid, A., Hedayati, J., & Ghayur, M. N. (2024) · Biochemistry Research International · doi:10.1155/bri/9192496 · Cited by 10
“Most cases of AD present in the early stage of disease progression [5], when patients begin to have problems with concentration, becoming disoriented, and mood changes [6].”
Sviben, M., Odak, I., Barić, D., Mlakić, M., Horváth, O., Fodor, L., Roca, S., Šagud, I., & Škorić, I. (2025) · Molecules · doi:10.3390/molecules30020316 · Cited by 10
“Alzheimer’s disease is a progressive neurodegenerative disease characterized by the deterioration of synapses and neurons in the cortical and subcortical regions of the brain and impairment of the function of nerve impulse transmitter systems [1,2].”
Safi, A., Giunti, E., Melikechi, O., Xia, W., & Melikechi, N. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42349 · Cited by 11
“This delay limits the potential impact of available treatments, many of which are most effective in the earlier stages of the disease [2].”
Functionalized Nanoparticles: A Promising Approach for Effective Management of Alzheimer’s Disease
Bogadi, S., Bhaskaran, M., Ravichandran, V., Nesamony, J., Selvam, C., Kuppusamy, G., Prakash, G., Karri, V. V. S. R., Mallick, S., Farahim, F., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04917-2 · Cited by 12
“Intranasal drug delivery systems offer a significant advantage over other delivery systems, and even these delivery systems have some drawbacks [10].”
Design and synthesis of benzyl aminocoumarin and its anti-Alzheimer's activity
Zhang, Q., Hao, C., Miao, Y., Yun, Y., Sun, X., Pan, Y., Sun, J., & Wang, X. (2021) · New Journal of Chemistry · doi:10.1039/d1nj02950a · Cited by 10
Soares, E. S., Souza, A. C. G., Zanella, C. A., Carmichael, R. E., Henley, J. M., Wilkinson, K. A., & Cimarosti, H. (2022) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2022.01.003 · Cited by 10
Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease
Zhuang, J., Gao, J., Yin, Y., Gong, B., Ji, W., Chen, X., Li, P., Cheng, W., Zhao, Y., & He, B. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220214092824 · Cited by 11
Lin, M., Li, P., Liu, W., Niu, T., & Huang, L. (2022) · Bioengineered · doi:10.1080/21655979.2022.2036918 · Cited by 11
“Moreover, cholinergic and amyloid hypotheses have been considered as the main causes of AD [4].”
BackgroundInfluentialAssociations of Polygenic Risk Score for Late-Onset Alzheimer's Disease With Biomarkers
Li, Q., Lv, X., Jin, F., Liao, K., Gao, L., & Xu, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.849443 · Cited by 13
“Alzheimer’s disease (AD) which accounts for about 70% of dementia is an irreversible progressive polygenic neurodegenerative disease with insidious onset (Kametani and Hasegawa, 2018; Breijyeh and Karaman, 2020; Tank et al., 2022).”
BackgroundTherapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease
Tyler, S. E. B., & Tyler, L. D. K. (2022) · Natural Products and Bioprospecting · doi:10.1007/s13659-022-00354-z · Cited by 10
Leblhuber, F., Geisler, S., Ehrlich, D., Steiner, K., Kurz, K., & Fuchs, D. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220920090919 · Cited by 10
Ahmad, F., Sachdeva, P., Sachdeva, B., Singh, G., Soni, H., Tandon, S., Rafeeq, M. M., Alam, M. Z., Baeissa, H. M., & Khalid, M. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00629-3 · Cited by 11
“Memantine, an N-methyl D-aspartate (NMDA) antagonist, is also used for the treatment of moderate to severe AD [2].”
VANL-100 Attenuates Beta-Amyloid-Induced Toxicity in SH-SY5Y Cells
Collins, A. E., Saleh, T. M., & Kalisch, B. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010442 · Cited by 11
“Since the currently available treatment options for AD such as donepezil, rivastigmine, and memantine [7,93,94] are ineffective in preventing, reversing, or slowing the progression of the disease and are primarily indicated for symptom management, it is necessary to explore alternative methods for preventing and treat…”
BackgroundHu, H., Mei, J., Cai, Y., Ding, H., Niu, S., Zhang, W., & Fang, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1090223 · Cited by 13
“The prevalence of Alzheimer’s disease (AD), a disease marked by progressive memory loss and cognitive deficits, is increasing (Broom et al., 2019; Breijyeh and Karaman, 2020).”
BackgroundInvestigation of Potential Drug Targets for Cholesterol Regulation to Treat Alzheimer’s Disease
Passero, M., Zhai, T., & Huang, Z. J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20136217 · Cited by 11
Zhao, M., Yimiao, L., Wang, H., Yu, C., Li-na, M., Hui, P., & Hao, L. I. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20230404.006 · Cited by 10
Evolution of genetic testing supports precision medicine for caring Alzheimer's disease patients
Bruni, A. C., Bernardi, L., & Maletta, R. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.08.004 · Cited by 12
Role and application of CRISPR-Cas9 in the management of Alzheimer’s disease
Soni, N., Kar, I., Narendrasinh, J. D., Shah, S. K., Konathala, L., Mohamed, N., Kachhadia, M. P., Chaudhary, M. H., Dave, V. A., Kumar, L., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001692 · Cited by 10
“• The potential of CRISPR-Cas9 technology outweighs it as currently the greatest gene-editing tool available for researching neurodegenerative diseases like AD. understood despite extensive investigation [4,5] .”
BackgroundYuan, Q., & Yang, Z.-K. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/175049 · Cited by 10
Histone deacetylase’s regulates Tau function in Alzheimer’s disease
Chinnathambi, S. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.09.008 · Cited by 27
Geldenhuys, W. J., Wilson, G. N., Hernandez, K., Monaghan, K., Smith, K., Cicala, D. S., Poling, T. J., Walton, J. C., Han, P., & Huber, J. D. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241302456 · Cited by 11
James, D. L., Larkey, L., Maxfield, M., Han, S., Ofori, E., Mohr, A. E., Hawley, N. A., Alperin, K., Ahlich, E. M., Vance, D. E., et al. (2024) · Journal of Clinical and Translational Science · doi:10.1017/cts.2024.676 · Cited by 15
“AD is the most prevalent form of dementia and is a progressive, neurodegenerative disease characterized by impaired memory, judgment, and the ability to carry out activities of daily living [5].”
Naeem, A., Waseem, A., Khan, M. A., Robertson, A. A. B., & Raza, S. S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04662-y · Cited by 10
“Furthermore, the affected areas of the brain exhibit intraneuronal accumulations of hyperphosphorylated tau protein and neuronal cell death [7].”
Udo, M. S. B., Zaccarelli‐Magalhães, J., Clemons, G. A., Citadin, C. T., Langman, J., Smith, D. J., Matuguma, L. H., Tešić, V., & Lin, H. W. (2025) · GeroScience · doi:10.1007/s11357-025-01526-8 · Cited by 9
“The multi-factorial aspects of AD pathology pose various treatment challenges [11], therefore targeting novel pathways that contribute to AD progression is crucial due to limited treatment modalities.”
Abbott, V., Housden, B. E., & Houldsworth, A. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf092 · Cited by 12
Quan, Q., Ma, X., Feng, J., Li, W., & Li, X. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102514 · Cited by 9
Sarkar, S., Porel, P., Kosey, S., & Aran, K. R. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01697-y · Cited by 9
“Approximately 50 million people worldwide currently suffer from AD, a number projected to double every five years and eventually reach 152 million by the year 2050 (Breijyeh and Karaman 2020).”
Alikhanzade, M., Khosravi, M., Hosseini, M., & Rajabian, A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01699-w · Cited by 12
“Regret-tably, current predictions indicate that approximately 10% of the population over the age of 65 will be impacted by this disease, posing a substantial challenge for the World Health Organization (WHO) (Breijyeh and Karaman 2020; Bhatt et al. 2021; Chen et al. 2022).”
The aggregation propensity of Tau and amyloid-β in Alzheimer’s disease
Chinnathambi, S., Kumarappan, M., Chandrshekar, M., & Malik, S. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.10.004 · Cited by 19
Eciroglu, H., Çelik, P. A., Kelicen‐Uğur, P., & Dönmez‐Altuntaş, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05082-2 · Cited by 11
“Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment and the loss of functional abilities [1].”
InfluentialBiological applications of graphene-based nanomaterials in neurodegenerative diseases
Zhu, R.-K., Shi, J. Y., Zhou, H.-J., Ge, L., Yin, W.-H., Zeng, H., & Wang, X. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102064 · Cited by 13
“Each subtype exhibits characteristic biomarkers: AD presents with A β plaques and hyperphosphorylated tau neurofibrillary tangles [8,9], PD demonstrates α -syn-containing Lewy bodies [10], while ALS correlates with TDP-43 proteinopathy [11].”
Cont, C., Stute, N., Galli, A., Schulte, C. E., & Wojtecki, L. (2025) · Brain Sciences · doi:10.3390/brainsci15080830 · Cited by 9
“As the “baby boomer” generation ages, the number of those affected by AD is projected to double every 5 years and is predicted to reach 152 million by 2050 [1].”
Lei, H.-P., Yang, X., Hu, Y., Wu, L.-N., Wei, A., Yu, L., Liu, T., Ji, X., Liu, J., Jin, H. J., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120548 · Cited by 11
Regulation of NR4A2 Gene Expression and Its Importance in Neurodegenerative and Psychiatric Diseases
Ruiz-Sánchez, E., Rojas, C., Gómez, P. Y., Martínez‐Rodríguez, N., Ruíz-Chow, Á. A., Nava-Ruíz, C., Ibáñez-Cervantes, G., Arciniega-Martínez, I. M., Reséndiz‐Albor, A. A., & Rojas, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189162 · Cited by 10
“It is characterized by a significant decline in cognitive abilities that results in an increased need for assistance with daily activities [154].”
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.